Multi-billion dollar corporate middlemen — PBMs — have come under intense scrutiny for driving up the cost of medicines for their own financial gain. PBMs’ shell games have negatively impacted patients, small businesses, local pharmacies, state governments, and taxpayers for years.

**DID YOU KNOW?**

Pharmacies were hit with an estimated **$9.1 billion** in fees from PBMs in 2019 compared to **$229 million** in 2013. The total amount of pharmacy DIR fees from PBMs increased by **450 times** from 2010 to 2017.

The top three PBMs created their own group purchasing organizations (GPOs) — two of which are located overseas — adding another layer of complication to the drug pricing process.

PBM-affiliated pharmacies are making **18 to 109 times more profit** over the cost of the drugs than the typical community pharmacy.

Only three PBMs process about **80%** of all equivalent prescription drug claims.

Five of the six largest PBMs are closely tied to health insurance companies.

PBMs pocketed more than **$492 billion** in revenue in 2022 — up from **$197 billion** in 2012: a 250% increase.

3. https://www.drugchannels.net/2023/01/the-big-three-pbms-2023-formulary.html#:~:text=These%20criteria%20have%20led%20many,one%20year%20from%20one%20PBM.
7. https://www.drugchannels.net/2023/05/the-top-pharmacy-benefit-managers-of.html

To learn more about harmful PBM practices and potential policy solutions, visit pbmaccountability.org